Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases

The novel antibody demonstrates potent depletion of B cells and plasma cells with favorable safety profile in preclinical studies

Apr. 10, 2026 at 2:18am

Got story updates? Submit your updates here. ›

An abstract X-ray-like image showing the complex structure of lymphoid tissue, highlighting the key immune cells involved in autoimmune disorders.A novel tri-specific antibody aims to precisely target and deplete the immune cells driving autoimmune diseases.Boston Today

Innovent Biologics presented the preclinical data of IBI3055, a proprietary anti-CD19/BCMA/CD3 tri-specific T cell engager, at the 2026 Immune Resetting: B-Cell Mediated & Beyond Summit. IBI3055 is designed to achieve an optimal balance between potent immune cell depletion and favorable safety profile for the treatment of various B cell- or plasma cell-mediated autoimmune diseases.

Why it matters

Autoimmune diseases driven by B cells or plasma cells remain an area of significant unmet medical need, requiring innovative therapies capable of inducing deep immune cell depletion and immune resetting to deliver durable clinical benefits. IBI3055's unique design aims to provide a safer and more effective treatment option for patients.

The details

IBI3055 employs a "1+1+1" design with CD3 masking, enabling target-dependent T cell activation and potentially improving safety and pharmacokinetic properties. In preclinical studies, IBI3055 demonstrates effective cytotoxicity against CD19- or BCMA-positive cells, and induces deep depletion of B cells and plasma cells in multiple in vivo models, leading to significant reductions in circulating immunoglobulin levels. IBI3055 also shows favorable safety and tolerability in non-human primates.

  • IBI3055 data was presented at the 2026 Immune Resetting: B-Cell Mediated & Beyond Summit in Boston, Massachusetts on April 9, 2026.

The players

Innovent Biologics

A world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas.

IBI3055

Innovent's proprietary anti-CD19/BCMA/CD3 tri-specific T cell engager designed for the treatment of various B cell- or plasma cell-mediated autoimmune diseases.

Dr. Huizhong Xiong

Vice President of Immunology at Innovent.

Got photos? Submit your photos here. ›

What they’re saying

“Significant unmet medical needs remain in autoimmune diseases driven by B cells or plasma cells. There is an urgent need for innovative therapies capable of inducing deep immune cell depletion and immune resetting to deliver durable clinical benefits. Such therapies must balance potent efficacy with favorable tolerability. Through protein engineering and CD3 masking, IBI3055 is designed to achieve this balance and provide a safer and more effective treatment option for patients.”

— Dr. Huizhong Xiong, Vice President of Immunology at Innovent

What’s next

Innovent plans to further evaluate the safety and efficacy of IBI3055 in clinical trials for the treatment of various B cell- or plasma cell-mediated autoimmune diseases.

The takeaway

IBI3055's unique tri-specific T cell engager design with CD3 masking represents a promising approach to address the significant unmet need in autoimmune diseases, potentially offering a safer and more effective treatment option compared to current therapies.